|
市場調查報告書
藥品創新趨勢
Pharmaceutical Innovation: Is It Really Rewarded?
|
本報告已在2011年12月21日停止出版。
全球大規模藥品市場雖然關心新藥開發的發展，但是昂貴的新藥卻會更加加重稅負沈重的醫療制度的負擔。
專門於醫療產業相關廣泛調查的美國市調公司Decision Resources Inc.(總公司：Massachusetts State) 針對藥物的創新趨勢進行調查分析，並出版經系統整理的報告書"Pharmaceutical Innovation: Is It Really Rewarded?"。
本報告書內容包括：歐洲畫時代的新藥開發行動方案概要、歐洲、日本及美國畫時代新藥的未來償付趨勢、主要市場中的藥價動向等。內容綱要摘記如下：
實施概要
創新：利益及成本的平衡
EU
法國
- 標準藥價制定順序
- 畫時代新藥的藥價制定
- 藥價及償付的更新
德國
- 參考價格
- 處方預算
- 醫療技術評價
- 針對高價位藥物的新規範
義大利
西班牙
英國
- 藥價規範制度的替代方案
- National Institute for Clinical Excellence
- 重新檢討NICE許可的癌症治療藥出現的參差不齊狀況
- 針對藥物難以得手之患者的因應辦法
- 更快的NICE許可流程
日本
美國
- 民間領域的正式決策
- Medicare對醫療經濟研究的贊助
藥品產業未來發展預測及影響
表
- 日本針對新藥的藥價制定方法：2002年6月至2007年3月
- 日本的國民健康保險制度
- 針對治療的新藥價格優惠數量：2002年6月至2007年3月
- 美國雇主對提高處方藥津貼策略的看法
圖
- 主要市場藥品支出額中的新藥部份：2001年至2004年
- 針對法國藥劑的各種SMR評分比例
- 針對法國藥劑的各種ASMR評分比例
- 日本利用在新處方藥上的藥價制定方法的決定標準
Abstract
Introduction
Governments in the world' s largest pharmaceutical markets clearly have an
interest in promoting access to innovative medicines, but the relatively high
price of many novel drugs can place a heavy fi nancial burden on overtaxed
health care systems. Thus, the essential challenge for governments and other
payers is to strike a balance between the benefi ts and costs of making
innovative medicines more widely available.
Get the Answers You Need to Shape Your Strategy
- The European Commission wants to balance strict price controls and free
market pricing. What initiatives has the EU undertaken to achieve this
balance? Which EU markets have the strictest constraints on pharmaceutical
pricing? Are new policies likely to improve or worsen the climate for
pharmaceutical companies?
- Recently, the Japanese government has taken action intended to make
premiums for innovation more generous and more attainable. What price reforms
has the government made? Are they likely to in fact encourage innovation? Will
the new price premiums be achievable?
- In the United States, the increasing focus on drug prices will prompt more
payers to adopt evidence-based formularies. How is formulary decision making
evolving in the private sector? How is Medicare now encouraging health
economic research?
Scope
- EU innovation initiatives: a review of recent initiatives by the EU in
support of innovative medicines in Europe.
- Outlook and implications for the pharmaceutical industry: the future of
reimbursement for innovative drugs in the EU, Japan, and the United States.
- Detailed analysis of pricing and reimbursement in the major markets: an
examination of how health care payers in seven leading pharmaceutical markets
(France, Germany, Italy, Spain, United Kingdom, Japan, and United States)
approach the pricing and reimbursement of innovative drugs.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Innovation: Balancing Benefi ts and Costs
- European Union
- High-Level Group on Innovation and the Provision of Medicines (G10
Medicines Group)
- High-Level Pharmaceutical Forum
- France
- Standard Price-Setting Procedure
- Price Setting for Innovative Drugs
- Renewal of Pricing and Reimbursement
- Germany
- Reference Pricing
- Prescribing Budgets
- Health Technology Assessment
- New Restrictions on the Use of Costly Drugs
- Italy
- Spain
- Price Setting
- Prior Authorization
- More Selective Funding of Medicines
- United Kingdom
- Proposal to Replace the Pharmaceutical Price Regulation Scheme
- National Institute for Clinical Excellence
- Review of Variations in the Use of NICE-Approved Cancer Drugs
- Patient Action Against Lack of Access to Certain Drugs
- Accelerated NICE Appraisal Process
- Japan
- Initial Pricing of Branded Prescription Drugs
- Similar-Effi cacy Comparison Methods
- Cost Calculation Method
- Price Premiums
- United States
- Formulary Decision Making in the Private Sector
- Medicare Sponsorship of Health Economic Research
- Outlook and Implications for the Pharmaceutical Industry
Tables:
- 1. Methods Used for Pricing New Drugs in Japan, June 2002-March 2007
- 2. Hierarchy of National Health Insurance Price Premiums in Japan
- 3. Number of New Drugs Awarded Price Premiums for Therapeutic Advances,
June 2002-March 2007
- 4. U.S. Employers' Views on Strategies to Increase Prescription Drug
Benefit Value
- 5. U.S. Employers' Views on Strategies to Increase Prescription Drug
Benefit Value
Figures:
- 1. New Drugs' Share of Total Pharmaceutical Expenditures in Major Markets,
2001-2004
- 2. Percentage of Drugs Awarded Various SMR Ratings in France
- 3. Percentage of Drugs Awarded Various ASMR Ratings in France
- 4. Criteria for Determining the Pricing Method Used for New Prescription
Drugs in Japan
|
